Reports Q2 revenue $103.2B, consensus $104.12B. “McKesson’s (MCK) second quarter results underscore the strength of our differentiated assets, capabilities, and continued momentum as a diversified healthcare services leader. We delivered record revenue in the quarter of $103 billion, increasing 10% and Adjusted Earnings per Diluted Share accelerating 39% compared to the prior year. These results reflect disciplined execution of our enterprise strategy – advancing growth in oncology and multispecialty and biopharma services. We remain confident in our ability to create value for our customers, partners, employees, and shareholders,” said Brian Tyler, chief executive officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- Cencora price target raised to $345 from $315 at BofA
- McKesson price target raised to $900 from $850 at BofA
- MCK Earnings this Week: How Will it Perform?
- McKesson price target raised to $920 from $860 at UBS
- Trump Trade: Trump administration prepares new probe into pharma prices